Operating Lease, Right-of-Use Asset of NEKTAR THERAPEUTICS from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
NEKTAR THERAPEUTICS quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • NEKTAR THERAPEUTICS Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $7,171,000, a 19% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

NEKTAR THERAPEUTICS Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $7,171,000 -$1,655,000 -19% 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 $7,585,000 -$1,655,000 -18% 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $7,999,000 -$9,268,000 -54% 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $8,413,000 -$9,594,000 -53% 31 Dec 2024 10-Q 07 Nov 2025 2025 Q3
Q3 2024 $8,826,000 -$9,921,000 -53% 30 Sep 2024 10-Q 08 Nov 2024 2024 Q3
Q2 2024 $9,240,000 -$19,775,000 -68% 30 Jun 2024 10-Q 09 Aug 2024 2024 Q2
Q1 2024 $17,267,000 -$24,920,000 -59% 31 Mar 2024 10-Q 10 May 2024 2024 Q1
Q4 2023 $18,007,000 -$35,428,000 -66% 31 Dec 2023 10-K 14 Mar 2025 2024 FY
Q3 2023 $18,747,000 -$47,149,000 -72% 30 Sep 2023 10-Q 08 Nov 2023 2023 Q3
Q2 2023 $29,015,000 -$39,981,000 -58% 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $42,187,000 -$72,109,000 -63% 31 Mar 2023 10-Q 10 May 2023 2023 Q1
Q4 2022 $53,435,000 -$63,590,000 -54% 31 Dec 2022 10-K 05 Mar 2024 2023 FY
Q3 2022 $65,896,000 -$53,818,000 -45% 30 Sep 2022 10-Q 04 Nov 2022 2022 Q3
Q2 2022 $68,996,000 -$53,366,000 -44% 30 Jun 2022 10-Q 05 Aug 2022 2022 Q2
Q1 2022 $114,296,000 -$10,675,000 -8.5% 31 Mar 2022 10-Q 06 May 2022 2022 Q1
Q4 2021 $117,025,000 -$9,451,000 -7.5% 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q3 2021 $119,714,000 -$9,271,000 -7.2% 30 Sep 2021 10-Q 05 Nov 2021 2021 Q3
Q2 2021 $122,362,000 -$9,096,000 -6.9% 30 Jun 2021 10-Q 06 Aug 2021 2021 Q2
Q1 2021 $124,971,000 -$8,930,000 -6.7% 31 Mar 2021 10-Q 07 May 2021 2021 Q1
Q4 2020 $126,476,000 -$7,701,000 -5.7% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $128,985,000 -$5,903,000 -4.4% 30 Sep 2020 10-Q 06 Nov 2020 2020 Q3
Q2 2020 $131,458,000 +$49,281,000 +60% 30 Jun 2020 10-Q 07 Aug 2020 2020 Q2
Q1 2020 $133,901,000 +$50,426,000 +60% 31 Mar 2020 10-Q 08 May 2020 2020 Q1
Q4 2019 $134,177,000 +$134,177,000 31 Dec 2019 10-K 26 Feb 2021 2020 FY
Q3 2019 $134,888,000 30 Sep 2019 10-Q 07 Nov 2019 2019 Q3
Q2 2019 $82,177,000 30 Jun 2019 10-Q 09 Aug 2019 2019 Q2
Q1 2019 $83,475,000 31 Mar 2019 10-Q 09 May 2019 2019 Q1
Q4 2018 $0 31 Dec 2018 10-K 28 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.